Polyoxidonium - instructions for use, analogs, reviews and release forms (tablets 12 mg, suppositories 6 mg and 12 mg, injections in ampoules for injection of 3 mg and 6 mg) of the drug for the treatment of immunodeficiency in adults, children and pregnancy

In this article, you can read the instructions for using the drug Polyoxidonium. There are reviews of visitors to the site - consumers of this medication, as well as opinions of physicians specialists on the use of Polyoxidonium in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Polyoxidonium in the presence of existing structural analogues.Use for the treatment of immunodeficiency and related infectious diseases in adults, children, as well as in pregnancy and lactation.

Polyoxidonium - immunomodulating drug.

Polyoxidonium has an immunomodulatory effect, increases the body's resistance to local and generalized infections. The basis of the mechanism of immunomodulatory action of Polyoxidonium is a direct effect on phagocytic cells and natural killers, as well as stimulation of antibody formation.

Polyoxidonium restores immunity to secondary immunodeficiency states caused by various infections, traumas, burns, autoimmune diseases, malignant neoplasms, complications after surgical operations, the use of chemotherapeutic agents, cytostatics, steroid hormones.

Along with immunomodulating action. Polyoxidonium has a pronounced detoxification and antioxidant activity, has the ability to excrete toxins from the body, salts of heavy metals, inhibits lipid peroxidation.These properties are determined by the structure and high molecular weight of the preparation Polyoxidonium. Including it in the complex therapy of cancer patients reduces intoxication on the background of chemo- and radiotherapy, in most cases it allows to carry out standard therapy without changing the scheme due to the development of infectious complications and side effects (myelosuppression, vomiting, diarrhea, cystitis, colitis and others).

The use of Polyoxidonium on the background of secondary immunodeficiency states allows to increase the efficiency and shorten the duration of treatment, significantly reduce the use of antibiotics, bronchodilators, GCS, and extend the duration of remission.

The drug is well tolerated, does not have mitogenic, polyclonal activity, antigenic properties, does not have allergic, mutagenic, embryotoxic, teratogenic and carcinogenic effects.

Pharmacokinetics

Polyoxidonium after intake is rapidly absorbed from the digestive tract, bioavailability is approximately 50%. Pharmacokinetics Polyoxidonium is linear (concentration in the blood plasma is proportional to the dose taken). In the body it is hydrolyzed to oligomers, which are excreted mainly by the kidneys.Cumulative effect is absent (does not accumulate in the body).

Composition

Azoxymer bromide + auxiliary substances.

Indications

Correction of immunity in adults and children from 6 months.

In adults in complex therapy:

• chronic recurrent infectious and inflammatory diseases, which can not be standardized at the stage of exacerbation and remission;
• acute and chronic viral and bacterial infections (including urogenital infectious and inflammatory diseases);
• tuberculosis;
• acute and chronic allergic diseases (including pollinosis, bronchial asthma, atopic dermatitis), complicated by a chronic recurrent bacterial and viral infection;
• in oncology in the course and after chemotherapy and radiation therapy to reduce immunosuppressive, nephro- and hepatotoxic effects of drugs;
• for activation of regenerative processes (fractures, burns, trophic ulcers);
• Rheumatoid arthritis, long-term treated with immunosuppressants;
• with complicated ARI course of rheumatoid arthritis;
• for the prevention of postoperative infectious complications;
• for the prevention of influenza and acute respiratory disease.

In children in complex therapy:

• acute and chronic inflammatory diseases caused by pathogens of bacterial, viral, fungal infections (including ENT organs - sinusitis, rhinitis, adenoiditis, pharyngeal tonsillitis hypertrophy, ARVI);
• acute allergic and toxic-allergic conditions;
• A bronchial asthma complicated by chronic infections of the respiratory tract;
• atopic dermatitis, complicated by a purulent infection;
• intestinal dysbiosis (in combination with specific therapy);
• for rehabilitation often and long-term ill;
• prevention of influenza and acute respiratory infections.

Forms of release

Tablets 12 mg.

Candles for vaginal or rectal administration of 6 mg and 12 mg.

Lyophilizate for solution for injection and topical application (injections in ampoules) 3 mg and 6 mg.

Instructions for use and dosing regimen

Pills

Polyoxidonium tablets are administered orally and sublingually for 20-30 minutes before meals daily 1, 2 or 3 times a day: adults - in doses of 12 mg or 24 mg, adolescents from 12 years - at a dose of 12 mg. The method and dosage regimen is determined by the doctor depending on the diagnosis, severity and severity of the process.

Sublingually

In inflammatory diseases of the oral cavity and pharynx (bacterial, viral or fungal nature), Polyoxidonium is prescribed in a dose of 12 mg (1 tablet) 2 times a day at intervals of 12 hours for 10-14 days.

In severe forms of herpetic or fungal infection of the oral cavity - in a dose of 12 mg 3 times a day at an interval of 8 hours for 15 days.

In chronic sinusitis and chronic otitis media - 12 mg (1 tablet) 2 times a day for 5-10 days.

In chronic tonsillitis - 12 mg (1 tablet) 3 times a day with an interval of 8 hours for 10-15 days.

For chronic diseases of the upper respiratory tract to adults - in a dose of 24 mg (2 tablets) 2 times a day, adolescents - in a dose of 12 mg (1 tablet) 2 times a day at an interval of 12 hours for 10-14 days.

For prevention of influenza and acute respiratory infections in immunocompromised patients suffering from acute respiratory disease more than 4 times a year, preepidemic period of drug administered to adults at a dose of 24 mg (2 tablets), 2 times a day, adolescents in a dose of 12 mg (1 tablet), 2 times a day within 10-15 days.

Orally

In chronic diseases of the upper respiratory tract polioksidony adult is administered in a dose of 24 mg (2 tablets), 2 times a day at intervals of 12 hours, teenagers - a dose of 12 mg (1 tablet), 2 times a day at intervals of 12 hours during 10-14 days.

Candles

The drug is intended for rectal and intravaginal administration of 1 candle once a day. The method and dosage regimen is determined by the doctor depending on the diagnosis, severity and severity of the process. The drug can be used daily, every other day or twice a week.

Suppositories 12 mg are used in adults rectally and intravaginally.

Suppositories 6 mg are used in children over 6 years of age rectally; in adults rectally and intravaginally as maintenance therapy.

Rectal suppositories are injected into the rectum after cleansing the intestine. Intravaginal suppositories are injected into the vagina in the supine position once a day for the night.

Standard Application Scheme

1 suppository 6 mg or 12 mg once a day daily for 3 days, then a day later with a course of 10-20 suppositories.

If necessary, the course of treatment is repeated after 3-4 months.

Patients with chronic immune deficiency (including long-term immunosuppressive therapy, with oncological diseases, exposed HIV) have a sustained maintenance period of 2-3 months to 1 year with Polyoxidonium (adults 12 mg, children over 6 years of age - according to 6 mg 1-2 times a week).

Variants of recommended regimens for use in complex therapy

In chronic infectious and inflammatory diseases in the stage of exacerbation - according to the standard scheme, in the remission phase - 1 suppository 12 mg after 1-2 days, the general course of 10-15 suppositories.

In acute infectious processes and for the activation of regenerative processes (fractures, burns, trophic ulcers) - 1 suppository daily. The course of treatment - 10-15 suppositories.

With tuberculosis the drug is prescribed according to the standard scheme. The course of treatment - at least 15 candles, then it is possible to use maintenance therapy for 2 suppositories per week for up to 2-3 months.

Against the backdrop of chemo-and radiation therapy of tumors, one suppository is administered every day 2-3 days before the start of the course of therapy. Further, the frequency of administration of suppositories is determined by the doctor, depending on the nature and duration of chemo- and radiotherapy.

For rehabilitation often (more than 4-5 times a year) and long-term ill persons and with rheumatoid arthritis - 1 candle every other day. The course of treatment - 10-15 suppositories.

For correction of secondary immunodeficiencies, incl. arising from aging, Polyoxidonium is used for 12 mg (1 supp.) 2 times a week.Course - not less than 10 suppositories 2-3 times a year.

As a monotherapy

For seasonal prevention of exacerbations of chronic infectious diseases and for the prevention of recurrent herpetic infection, the drug is used every other day for 6-12 mg in adults and 6 mg for children. Course - 10 suppositories.

For correction of secondary immunodeficiencies, prevention of influenza and acute respiratory disease, the drug is prescribed according to the standard scheme.

With gynecological diseases the drug is administered rectally and intravaginally according to the standard scheme.

Side effect

• soreness at the injection site with intramuscular injection.

Contraindications

• children's age till 12 years;
• increased individual sensitivity to the drug.

Application in pregnancy and lactation

Application in pregnancy and lactation is contraindicated (clinical experience is not available).

Excretion Polyoxidonium with breast milk has not been studied.

special instructions

Do not exceed these doses and the duration of treatment.

When painful at the injection site with intramuscular injection, the drug is dissolved in 1 ml of 0.25% solution of procaine if the patient has no increased individual sensitivity to procaine.

When intravenous (drip) administration should not be dissolved in protein-containing infusion solutions.

Impact on the ability to drive vehicles and manage mechanisms

Does not affect the ability to drive cars and control mechanisms.

Drug Interactions

Drug interaction is not established.

Polyoxidonium is compatible with antibiotics, antiviral, antifungal and antihistamine drugs, bronchodilators, GCS, cytostatics, beta-adrenomimetics.

Analogues of the drug Polyoxidonium

Structural analogues of the active substance drug Polyoxidonium does not.

Similar medicines:

Other medicines: